Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Research

A Clinical Score for Predicting Atrial Fibrillation in Patients with Cryptogenic Stroke or Transient Ischemic Attack

Kwong C.a · Ling A.Y.c · Crawford M.H.e · Zhao S.X.b · Shah N.H.d

Author affiliations

aDepartment of Medicine and bDivision of Cardiology, Santa Clara Valley Medical Center, San Jose, CA, cBiomedical Informatics Training Program, Stanford University, and dCenter for Biomedical Informatics Research, Stanford University School of Medicine, Stanford, CA, and eUniversity of California San Francisco, San Francisco, CA, USA

Related Articles for ""

Cardiology 2017;138:133-140

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: January 04, 2017
Accepted: April 25, 2017
Published online: June 28, 2017
Issue release date: November 2017

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 3

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD

Abstract

Objectives: Detection of atrial fibrillation (AF) in post-cryptogenic stroke (CS) or transient ischemic attack (TIA) patients carries important therapeutic implications. Methods: To risk stratify CS/TIA patients for later development of AF, we conducted a retrospective cohort study using data from 1995 to 2015 in the Stanford Translational Research Integrated Database Environment (STRIDE). Results: Of the 9,589 adult patients (age ≥40 years) with CS/TIA included, 482 (5%) patients developed AF post CS/TIA. Of those patients, 28.4, 26.3, and 45.3% were diagnosed with AF 1-12 months, 1-3 years, and >3 years after the index CS/TIA, respectively. Age (≥75 years), obesity, congestive heart failure, hypertension, coronary artery disease, peripheral vascular disease, and valve disease are significant risk factors, with the following respective odds ratios (95% CI): 1.73 (1.39-2.16), 1.53 (1.05-2.18), 3.34 (2.61-4.28), 2.01 (1.53-2.68), 1.72 (1.35-2.19), 1.37 (1.02-1.84), and 2.05 (1.55-2.69). A risk-scoring system, i.e., the HAVOC score, was constructed using these 7 clinical variables that successfully stratify patients into 3 risk groups, with good model discrimination (area under the curve = 0.77). Conclusions: Findings from this study support the strategy of looking longer and harder for AF in post-CS/TIA patients. The HAVOC score identifies different levels of AF risk and may be used to select patients for extended rhythm monitoring.

© 2017 S. Karger AG, Basel


References

  1. Mohan KM, Wolfe CDA, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP: Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke J Cereb Circ 2011;42:1489-1494.
  2. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C: Long-term risk of recurrent stroke after a first-ever stroke: the Oxfordshire Community Stroke Project. Stroke J Cereb Circ 1994;25:333-337.
  3. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke J Cereb Circ 1991;22:983-988.
  4. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke J Cereb Circ 2014;45:2160-2236.
  5. Medi C, Hankey GJ, Freedman SB: Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke J Cereb Circ 2010;41:2705-2713.
  6. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al: Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467-2477.
  7. Sanna T, Diener H-C, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al: Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478-2486.
  8. Jung K, LePendu P, Iyer S, Bauer-Mehren A, Percha B, Shah NH: Functional evaluation of out-of-the-box text-mining tools for data-mining tasks. J Am Med Inform Assoc 2015;22:121-131.
  9. LePendu P, Iyer SV, Bauer-Mehren A, Harpaz R, Mortensen JM, Podchiyska T, et al: Pharmacovigilance using clinical notes. Clin Pharmacol Ther 2013;93:547-555.
  10. Cole TS, Frankovich J, Iyer S, Lependu P, Bauer-Mehren A, Shah NH: Profiling risk factors for chronic uveitis in juvenile idiopathic arthritis: a new model for EHR-based research. Pediatr Rheumatol Online J 2013;11:45.
  11. Unitex/GramLab. http://unitexgramlab.org (accessed June 17, 2017).
  12. Wu ST, Liu H, Li D, Tao C, Musen MA, Chute CG, et al: Unified Medical Language System term occurrences in clinical notes: a large-scale corpus analysis. J Am Med Inform Assoc 2012;19:e149-e156.
  13. Harkema H, Dowling JN, Thornblade T, Chapman WW: Context: an algorithm for determining negation, experiencer, and temporal status from clinical reports. J Biomed Inform 2009;42:839-851.
  14. Goldstein LB: Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: effect of modifier codes. Stroke J Cereb Circ 1998;29:1602-1604.
  15. Bugnicourt J-M, Flament M, Guillaumont M-P, Chillon J-M, Leclercq C, Canaple S, et al: Predictors of newly diagnosed atrial fibrillation in cryptogenic stroke: a cohort study. Eur J Neurol 2013;20:1352-1359.
  16. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al: Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96:2455-2461.
  17. Lipsky BA, Weigelt JA, Sun X, Johannes RS, Derby KG, Tabak YP: Developing and validating a risk score for lower-extremity amputation in patients hospitalized for a diabetic foot infection. Diabetes Care 2011;34:1695-1700.
  18. Sullivan LM, Massaro JM, D'Agostino RB: Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 2004;23:1631-1660.
  19. Leisenring W, Alonzo T, Pepe MS: Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics 2000;56:345-351.
  20. R Core Team: R: a language and environment for statistical computing. https://www.R-project.org/.
  21. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-272.
  22. Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJB, Demaerschalk BM, et al: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke J Cereb Circ 2013;44:870-947.
  23. Malik S, Hicks WJ, Schultz L, Penstone P, Gardner J, Katramados AM, et al: Development of a scoring system for atrial fibrillation in acute stroke and transient ischemic attack patients: the LADS scoring system. J Neurol Sci 2011;301:27-30.
  24. Suissa L, Bertora D, Lachaud S, Mahagne MH: Score for the Targeting of Atrial Fibrillation (STAF): a new approach to the detection of atrial fibrillation in the secondary prevention of ischemic stroke. Stroke 2009;40:2866-2868.
  25. Favilla CG, Ingala E, Jara J, Fessler E, Cucchiara B, Messé SR, et al: Predictors of finding occult atrial fibrillation after cryptogenic stroke. Stroke J Cereb Circ 2015;46:1210-1215.
  26. Brunner KJ, Bunch TJ, Mullin CM, May HT, Bair TL, Elliot DW, et al: Clinical predictors of risk for atrial fibrillation: implications for diagnosis and monitoring. Mayo Clin Proc 2014;89:1498-1505.
  27. Suzuki S, Sagara K, Otsuka T, Kano H, Matsuno S, Takai H, et al: Usefulness of frequent supraventricular extrasystoles and a high CHADS2 score to predict first-time appearance of atrial fibrillation. Am J Cardiol 2013;111:1602-1607.
  28. Seet RCS, Friedman PA, Rabinstein AA: Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 2011;124:477-486.
  29. Sposato LA, Cipriano LE, Saposnik G, Ruíz Vargas E, Riccio PM, Hachinski V: Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2015;14:377-387.
  30. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, D'Agostino RB, et al: Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009;373:739-745.
  31. Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH: Assessment of the CHA2DS2-VASc ccore in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 2015;314:1030-1038.
  32. Mitchell LB, Southern DA, Galbraith D, Ghali WA, Knudtson M, Wilton SB, et al: Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart Br Card Soc 2014;100:1524-1530.
  33. Goudis CA, Korantzopoulos P, Ntalas IV, Kallergis EM, Ketikoglou DG: Obesity and atrial fibrillation: a comprehensive review of the pathophysiological mechanisms and links. J Cardiol 2015;66:361-369.
  34. Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, et al: Androgen deprivation therapy and future Alzheimer's disease risk. J Clin Oncol Off J Am Soc Clin Oncol 2016;34:566-571.

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: January 04, 2017
Accepted: April 25, 2017
Published online: June 28, 2017
Issue release date: November 2017

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 3

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.